CD123+CLL-1 dual-target CAR-T cells sequential infusion CD7 CAR-T cells and bridging to allogeneic
IIT2025079
Phase 1 mab active
Quick answer
CD123+CLL-1 dual-target CAR-T cells sequential infusion CD7 CAR-T cells and bridging to allogeneic for AML - Acute Myeloid Leukemia is a Phase 1 program (mab) at China SXT Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Program details
- Company
- China SXT Pharmaceuticals
- Indication
- AML - Acute Myeloid Leukemia
- Phase
- Phase 1
- Modality
- mab
- Status
- active